Adaptin Bio, Inc.
APTN
$6.20
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 978.60K | 775.00K | 896.90K | 1.18M | 788.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.14M | 1.37M | 1.68M | 1.52M | 850.50K |
| Operating Income | -1.14M | -1.37M | -1.68M | -1.52M | -850.50K |
| Income Before Tax | -1.15M | -1.37M | -1.68M | -1.52M | -603.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.15M | -1.37M | -1.68M | -1.52M | -603.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.15M | -1.37M | -1.68M | -1.52M | -603.10K |
| EBIT | -1.14M | -1.37M | -1.68M | -1.52M | -850.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.13 | -0.16 | -0.20 | -0.18 | -0.10 |
| Normalized Basic EPS | -0.08 | -0.10 | -0.12 | -0.11 | -0.10 |
| EPS Diluted | -0.13 | -0.16 | -0.20 | -0.18 | -0.10 |
| Normalized Diluted EPS | -0.08 | -0.10 | -0.12 | -0.11 | -0.10 |
| Average Basic Shares Outstanding | 8.70M | 8.48M | 8.46M | 8.45M | 5.83M |
| Average Diluted Shares Outstanding | 8.70M | 8.48M | 8.46M | 8.45M | 5.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |